baymondteo
commented on
$COMSovereign (COMS.US)$ up or down?
1
11
baymondteo
reacted to
$Grab Holdings (GRAB.US)$ No mercy today this black Friday that for sure. Reality cruel...
2
baymondteo
liked
$Grab Holdings (GRAB.US)$ There is no minimum, only lower.
Translated
4
2
1
baymondteo
liked
$Grab Holdings (GRAB.US)$ Fell into the pit again.
Translated
3
baymondteo
liked
$Grab Holdings (GRAB.US)$ On the first day, it was so embarrassing, useless, and garbage.
Translated
11
2
baymondteo
liked
$Grab Holdings (GRAB.US)$ Wondering how many singaporean watching this now? Smash the like button, I’m curious about the number. ![]()
![]()
94
10
baymondteo
liked
$Grab Holdings (GRAB.US)$
Relax. Grab has secured the license to be one of the digital bank in SG. There will be future projects for that.
Relax. Grab has secured the license to be one of the digital bank in SG. There will be future projects for that.
11
2
1
baymondteo
liked
$Ardelyx (ARDX.US)$
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
6
2
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)
baymondteo : Up!!!